Ginkgo Bioworks
DNA
312 hedge funds and large institutions have $312M invested in Ginkgo Bioworks in 2024 Q2 according to their latest regulatory filings, with 50 funds opening new positions, 67 increasing their positions, 111 reducing their positions, and 73 closing their positions.
7% more call options, than puts
Call options by funds: $1.09M | Put options by funds: $1.02M
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.6% less ownership
Funds ownership: 1.97% → 1.36% (-0.6%)
9% less funds holding
Funds holding: 342 → 312 (-30)
32% less first-time investments, than exits
New positions opened: 50 | Existing positions closed: 73
40% less repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 111
79% less capital invested
Capital invested by funds: $1.51B → $312M (-$1.19B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Advisers
New York
|
+$22.6M |
| 2 |
Two Sigma Investments
New York
|
+$14.4M |
| 3 |
D.E. Shaw & Co
New York
|
+$12.9M |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$11.6M |
| 5 |
Legal & General Group
London,
United Kingdom
|
+$11.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$124M |
| 2 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$73.5M |
| 3 |
NAMA
Nikko Asset Management Americas
New York
|
-$40.1M |
| 4 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
-$39.8M |
| 5 |
Morgan Stanley
New York
|
-$32.1M |
DNA Hedge Fund Activity: Q2 2024 in Review
312 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Ginkgo Bioworks (DNA) for Q2 2024, worth a combined $312M — down 79% from $1.51B a quarter earlier.
Sellers outnumbered buyers: 73 funds closed out of DNA and 50 opened new positions — a net loss of 23 holders — while 111 trimmed existing stakes and 67 added.
The largest buyer was Two Sigma Advisers, adding an estimated $22.6M. The largest seller was ARK Investment Management, cutting an estimated $124M.
- 312 institutional investors held Ginkgo Bioworks (DNA) as of Q2 2024, down from 342 in Q1 2024.
- Funds reported $312M of Ginkgo Bioworks stock for Q2 2024, down 79% quarter-over-quarter.
- 50 funds opened new Ginkgo Bioworks positions in Q2 2024 and 73 closed out, a net change of -23 holders.
- The largest Ginkgo Bioworks buyer in Q2 2024 was Two Sigma Advisers, an estimated $22.6M added.
- The largest Ginkgo Bioworks seller in Q2 2024 was ARK Investment Management, an estimated $124M sold.
Based on aggregated 13F filings for Q2 2024.